Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04065490 · ClinicalTrials.gov registry record · NA
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
A NA study of Dry Age-Related Macular Degeneration, sponsored by LumiThera.
- Active
- Registry status
- NA
- Development phase
- 96
- Enrollment target
- 11
- Study locations
NCT04065490 is a NA study of Dry Age-Related Macular Degeneration that is active but no longer recruiting, run by LumiThera. The registered enrollment target is 96 participants, above the 70-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target (37% higher). The trial reports 11 study locations across 9 states.
The verdict
NCT04065490, a NA study of Dry Age-Related Macular Degeneration, is active but no longer recruiting, sponsored by LumiThera.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
- 11
- Study locations
Study Summary
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
Conditions Studied
Interventions
- DEVICE Valeda PBM treatment
- DEVICE Valeda Sham treatment
Study Locations (11)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- Stanford University - Palo Alto
Texas
- Gulf Coast Eye Institute - McAllen
- Retina Consultants of Houston - The Woodlands
Florida
- Florida Eye Clinic - Altamonte Springs
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
New Jersey
- Mid Atlantic Retina - Cherry Hill
New York
- New York Ear and Eye Infirmary - New York
North Carolina
- Duke Eye Center - Durham
Pennsylvania
- Cumberland Valley Retina Consultants - Chambersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2022-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04065490
The ClinicalTrials.gov registry entry for NCT04065490 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 70-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target (37% higher). The listed sponsor is LumiThera, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Valeda PBM treatment is the first listed.
NCT04065490 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT04065490 about?
NCT04065490 is a clinical study titled "Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)". This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
What is the current status of trial NCT04065490?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2019-09-01. Estimated completion is 2022-06-01.
What conditions does trial NCT04065490 study?
This clinical trial studies the following conditions: Dry Age-Related Macular Degeneration.
What interventions are being tested in trial NCT04065490?
The interventions under investigation include: Valeda PBM treatment (DEVICE), Valeda Sham treatment (DEVICE).
Who is sponsoring clinical trial NCT04065490?
This trial is sponsored by LumiThera, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04065490 being conducted?
This trial has 11 study locations across California, Florida, Maryland, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRIMA US-Feasibility Study in Atrophic Dry AMD
ACTIVE NOT RECRUITING · NA
-
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
COMPLETED · NA
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.